Primary cutaneous anaplastic large cell lymphoma
MONDO:0017598Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a rare T-cell non-Hodgkin lymphoma that affects the skin and generally shows no extracutaneous involvement at presentation. It belongs to the spectrum of primary cutaneous CD30+ lymphoproliferative disorders along with lymphomatoid papulosis with which it shares overlapping clinical and histopathologic features.
Also known as: ALCL, cutaneous, C-ALCL, anaplastic large-cell lymphoma, primary cutaneous type, primary C-ALCL, primary anaplastic large cell lymphoma of skin, primary anaplastic large cell lymphoma of the skin, primary cutaneous CD30 Positive anaplastic large cell lymphoma, primary cutaneous CD30+ ALCL
3154 clinical trials for this condition and its sub-types, 11 tagged with Primary cutaneous anaplastic large cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug shows promise for controlling rare skin cancers
Disease control OngoingThis study tests a drug called brentuximab vedotin in 79 people with rare skin lymphomas (ALCL, mycosis fungoides, or lymphomatoid papulosis) that have a marker called CD30. The goal is to see if the drug can shrink or control the cancer. Participants receive the drug every 3 wee…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Vitamin d boost may extend life in lymphoma patients, trial hopes
Disease control OngoingThis study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at tough lymphomas in first human test
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
AI reads skin biopsies to spot hidden lymphomas
Diagnosis OngoingThis study is developing and testing an artificial intelligence model that analyzes images of skin biopsies to tell the difference between malignant lymphomas (like mycosis fungoides) and benign conditions that look similar. The AI will be trained on hundreds of archived slides a…
Sponsor: Cairo University • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC